Tesofensine

What is tesofensine?

Tesofensine was originally developed by Neurosearch as a Parkinson's disease treatment — a neurological application targeting monoamine systems. In the Parkinson's trials, participants lost significant weight as a side effect. Neurosearch pivoted to obesity development, and the Phase IIb obesity trial (NN2330-1803) became one of the most-discussed weight loss drug trials of the late 2000s: 10.6% mean body weight loss over 24 weeks at 0.5 mg/day, with dose-dependent effects up to 12.8% at 1 mg/day.

The mechanism is triple monoamine reuptake inhibition — blocking the transporters for serotonin, dopamine, and norepinephrine simultaneously. This produces appetite suppression via central satiety signaling, increased basal metabolic rate via sympathetic nervous system activation, and dopaminergic reward pathway modulation that reduces food reward salience. The triple mechanism produces more robust weight loss than single or dual reuptake inhibitors (e.g., sibutramine, which was withdrawn over cardiovascular concerns).

Tesofensine was not pursued to Phase III by the original developer. It remains available as a research chemical. In the context of the current GLP-1 revolution, tesofensine occupies an interesting position: comparable weight loss magnitude to liraglutide (~10–11% vs. ~8%), faster onset (effects within weeks rather than months of gradual titration), but carrying cardiovascular risks that GLP-1 agonists do not — elevated heart rate and blood pressure from norepinephrine reuptake inhibition.

How it works

Triple Monoamine Reuptake Inhibition

Tesofensine blocks the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) — the same transporters targeted individually or in pairs by SSRIs, SNRIs, and bupropion. Blocking all three simultaneously produces: serotonergic satiety signaling (reduced appetite), dopaminergic reward pathway modulation (reduced food reward, altered eating behavior), and noradrenergic metabolic rate increase (elevated thermogenesis and energy expenditure via sympathetic activation).

Appetite Suppression via Central Satiety

The serotonin and norepinephrine components drive appetite suppression via hypothalamic satiety centers — the same mechanism exploited by older weight loss drugs (sibutramine). The dopamine component reduces the rewarding quality of food, changing the motivational relationship with eating rather than just creating satiety. This multi-axis appetite suppression is why the weight loss effect size exceeds single-mechanism reuptake inhibitors.

Long Half-Life — Practical Implications

Tesofensine's active metabolite has a half-life of approximately 220 hours (~9 days). Steady state takes approximately 3 weeks of daily dosing. This means: slow onset of full effect, slow offset if side effects develop — you cannot quickly stop and clear the compound. The very long half-life also means once-daily dosing produces stable plasma levels, avoiding the peaks and troughs of shorter-acting compounds.

What the research shows

Tesofensine vs. GLP-1 agonists — where it fits

Community knowledge

Tesofensine's community is primarily in the metabolic optimization and weight loss biohacker space — people who have specifically researched alternatives or complements to GLP-1 agonists, often those who didn't respond adequately to liraglutide or can't access semaglutide. The consistent community reports: significant and relatively rapid appetite suppression (effects within the first week at steady-state approach, faster than GLP-1's gradual titration), increased energy and motivation (consistent with dopamine and norepinephrine effects), and elevated resting heart rate — the most universally reported side effect, typically +5–10 bpm. Blood pressure monitoring is consistently discussed in community protocols as essential.